文献速递急性肾损伤

IL-17A预处理增强间充质干细胞对缺血再灌注急性肾损伤的疗效

IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathway.
PubMed 文献 · Kidney Int · 2017-11-11

该研究在小鼠缺血再灌注急性肾损伤模型中,比较了IL-17A预处理的间充质干细胞(MSCs)与普通MSCs的疗效。结果显示,IL-17A预处理MSCs能更显著降低急性肾小管坏死评分、血清肌酐和尿素氮,并增加调节性T细胞(Treg)比例。机制上,IL-17A通过上调COX-2增加PGE2产生,进而提升Treg百分比;敲除Treg或用塞来昔布阻断COX-2均逆转了上述获益。

要点

  • IL-17A预处理MSCs较普通MSCs更显著改善小鼠IRI-AKI的肾功能和病理。
  • IL-17A预处理MSCs通过COX-2/PGE2通路增加Treg比例,增强免疫抑制。
  • Treg敲除或COX-2阻断可逆转IL-17A预处理MSCs的附加获益。

核心结论

  • IL-17A预处理通过COX-2/PGE2通路增加Treg百分比,从而增强MSCs对小鼠缺血再灌注急性肾损伤的治疗效果。

研究设计与样本

  • 研究为动物实验,使用小鼠缺血再灌注急性肾损伤(IRI-AKI)模型,比较IL-17A预处理MSCs与普通MSCs的疗效。

主要发现

  • 与普通MSCs相比,IL-17A预处理MSCs显著降低小鼠急性肾小管坏死评分、血清肌酐和BUN。
  • IL-17A预处理MSCs显著增加共培养脾细胞中CD4+Foxp3+ Treg百分比,并降低刀豆蛋白A诱导的T细胞增殖。
  • IL-17A预处理MSCs治疗的小鼠血清IL-6、TNF-α、IFN-γ水平更低,血清IL-10水平及脾、肾Treg百分比更高。
  • 用PC61(抗CD25抗体)清除Treg可逆转IL-17A预处理MSCs的增强疗效。
  • IL-17A上调COX-2表达并增加PGE2产生;塞来昔布阻断COX-2可逆转IL-17A预处理MSCs对血清PGE2、Treg百分比、肾功能、病理评分及细胞因子的改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mesenchymal stem cells (MSCs) are effective for the management of experimental ischemia-reperfusion acute kidney injury (IRI-AKI). Immune modulation is one of the important mechanisms of MSCs treatment. Interleukin-17A (IL-17A) pretreated MSCs are more immunosuppressive with minimal changes in immunogenicity in vitro. Here, we demonstrated that administration of IL-17A-pretreated MSCs resulted in significantly lower acute tubular necrosis scores, serum creatinine, and BUN of mice with IRI-AKI, compared with the administration of MSCs. Of the co-cultured splenocytes, IL-17A-pretreated MSCs significantly increased the percentages of CD4+Foxp3+ Tregs and decreased concanavalin A-induced T cell proliferation. Furthermore, mice with IRI-AKI that underwent IL-17A-pretreated MSC therapy had significantly lower serum IL-6, TNF-α, and IFN-γ levels, a higher serum IL-10 level, and higher spleen and kidney Treg percentages than the mice that underwent MSCs treatment. Additionally, the depletion of Tregs by PC61 (anti-CD25 antibody) reversed the enhanced treatment efficacy of the IL-17A-pretreatedMSCs on mice with IRI-AKI. Additionally, IL-17A upregulated COX-2 expression and increased PGE2 production. The blockage of COX-2 by celecoxib reversed the benefit of IL-pretreated 17A-MSCs on the serum PGE2 concentration, spleen and kidney Tregs percentages, serum creatinine and BUN levels, renal acute tubular necrosis scores, and serum IL-6, TNF-α, IFN-γ, and IL-10 levels of IRI-pretreated mice with AKI, compared with MSCs. Thus, our results suggest that IL-17A pretreatment enhances the efficacy of MSCs on mice with IRI-AKI by increasing the Treg percentages through the COX-2/PGE2 pathway.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Bai M, Zhang L, Fu B, et al. IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathway. Kidney Int. 2017. PMID: 29132705. doi:10.1016/j.kint.2017.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。